<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:arxiv="http://arxiv.org/schemas/atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title>q-bio.CB updates on arXiv.org</title>
    <link>http://rss.arxiv.org/rss/q-bio.CB</link>
    <description>q-bio.CB updates on the arXiv.org e-print archive.</description>
    <atom:link href="http://rss.arxiv.org/rss/q-bio.CB" rel="self" type="application/rss+xml"/>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <language>en-us</language>
    <lastBuildDate>Wed, 01 Oct 2025 02:11:47 +0000</lastBuildDate>
    <managingEditor>rss-help@arxiv.org</managingEditor>
    <pubDate>Tue, 30 Sep 2025 00:00:00 -0400</pubDate>
    <skipDays>
      <day>Sunday</day>
      <day>Saturday</day>
    </skipDays>
    <item>
      <title>Design principles of the cytotoxic CD8+ T-cell response</title>
      <link>https://arxiv.org/abs/2509.22997</link>
      <description>arXiv:2509.22997v1 Announce Type: cross 
Abstract: Cytotoxic T lymphocytes eliminate infected or malignant cells, safeguarding surrounding tissues. Although experimental and systems-immunology studies have cataloged many molecular and cellular actors involved in an immune response, the design principles governing how the speed and magnitude of T-cell responses emerge from cellular decision-making remain elusive. Here, we recast a T-cell response as a feedback-controlled program, wherein the rates of activation, proliferation, differentiation and death are regulated through antigenic, pro- and anti-inflammatory cues. We demonstrate how the speed and magnitude of T-cell responses emerge from optimizing signal-feedback to protect against diverse infection settings. We recover an inherent trade-off: infection clearance at the cost of immunopathology. We show how this trade-off is encoded into the logic of T-cell responses by hierarchical sensitivity to different immune signals. This model explains experimentally observed patterns of T-cell effector expansion regulation in mice. Extending our model to immune-based T-cell therapies for cancer tumors, we identify a trade-off between the affinity for tumor antigens ("quality") and the abundance ("quantity") of infused T-cells necessary for effective treatment. Finally, we show how therapeutic efficacy can be improved by targeted genetic perturbations to T-cells. Our findings offer a unified control-logic for cytotoxic T-cell responses and point to specific regulatory programs that can be engineered for more robust T-cell therapies.</description>
      <guid isPermaLink="false">oai:arXiv.org:2509.22997v1</guid>
      <category>physics.bio-ph</category>
      <category>q-bio.CB</category>
      <pubDate>Tue, 30 Sep 2025 00:00:00 -0400</pubDate>
      <arxiv:announce_type>cross</arxiv:announce_type>
      <dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
      <dc:creator>Obinna A. Ukogu, Zachary Montague, Gr\'egoire Altan-Bonnet, Armita Nourmohammad</dc:creator>
    </item>
  </channel>
</rss>
